Trabectedin and lurbinectedin also reduce the production of growth factors, angiogenic and pro-inflammatory mediators such as CCL2, IL-6, CXCL8, MIF, and IL-6 in cancer cells, monocytes, and TAMs [60, 61]. This evidence concerns the gene CXCL8 and cancer.